Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon Jul 28, 2011 11:04am
215 Views
Post# 18882879

RE: Bleeding out?

RE: Bleeding out?There are a few factors driving down the price at the moment:

1. HEM is a high beta small cap stock that is trading off in sentiment with the broader markets
2. FCC is going to close the lightsquared comment period in 2 days, so investors in HEM, TRMB, and RAVN continue to be skittish until everything is resolved (it's headline uncertainty, but HEM sales have NOT been impacted by these issues so it's simply irrational market behaviour)
3. HEM's stock always trades seasonally weak at this time of the year (if you are playing with small dollars and can trade in and out of positions then possible, although often challenging, to try and time the seasonality. If you own many shares as I and many others do then trading in and out makes no sense, and frankly isn't feasible when daily volume is only 100K shares, providing long-term conviction remains, which it does).
4. Earnings will be coming out in a couple of weeks (likely Aug 9th) and the street is getting nervous given past disapointments. This is a fairly big quarter for HEM and they need to prove the business is on track
5. Volume has dried up given lackluster summer trading

Net, net now is a great time to buy if you believe in the longer term story. The stock is ridiculously cheap at current levels, and like any good investor it's great to buy low and sell high (reminds me of when HEM was trading in the 60 cent to 70 cent range. Many sold while myself and others loaded up). The fundamental story and backdrop for HEM remain very much intact. Once the noise of lightsquared and other issues mentioned above abates we should get another stock pop.
Bullboard Posts